arrow
D

Denis Caillot

department of hematology
H指数:77
被引数:2.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Response profile and long-term outcomes in Cyclin D1-overexpressing multiple myeloma: insights from the CASSIOPEIA trial

Cyclin D1过表达多发性骨髓瘤的反应特征和长期结局:来自CASSIOPEIA试验的见解

2026-07-030
OAAI
35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience

35年专注于高剂量疗法和自体干细胞移植的学术研究:法国骨髓瘤研究组(IFM)的经验

2025-10-240
OA
Poor Outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study

从ide-cel早期复发后使用靶向BCMA的双特异性抗体治疗效果不佳:一项法国真实世界研究

2025-09-200
OAAI
Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results

达拉妥单抗-硼替佐米-沙利度胺-地塞米松用于新诊断的骨髓瘤:CASSIOPEIA微小残留病结果

Blood
IF23.1
2025-03-260
OA
Hematopoietic stem cell transplantation for DLBCL: a report from the European Society for Blood and Marrow Transplantation on more than 40,000 patients over 32 years
2024-07-051
OAAI
Early Chimeric Antigen Receptor T Cell Expansion Is Associated with Prolonged Progression-Free Survival for Patients with Relapsed/Refractory Multiple Myeloma Treated with Ide-Cel: A Retrospective Monocentric Study
2024-06-012
PRE
Long-term outcome after autologous BCR::ABL1-negative peripheral blood stem cell transplantation in adults with Philadelphia-positive acute lymphoblastic leukemia: a comparative study
2023-11-300
OAAI
Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma
2023-11-024
OAAI
Prognostic impact of translocation t(14;16) in multiple myeloma according to the presence of additional genetic lesions
2023-10-2611
OAAI
Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT
2023-10-0199
OAAI
Clinical characteristics and outcome of 318 families with familial monoclonal gammopathy: A multicenter Intergroupe Francophone du Myelome study
2023-01-010
OA
Prognostic value of positron emission tomography/computed tomography in transplant-eligible newly diagnosed multiple myeloma patients from CASSIOPEIA: the CASSIOPET study

正电子发射断层扫描/计算机断层扫描在仙后座可移植的新诊断多发性骨髓瘤患者中的预后价值: CASSIOPET研究

2022-10-2010
OAAI
Evaluation of Serum Mucorales Polymerase Chain Reaction (PCR) for the Diagnosis of Mucormycoses: The MODIMUCOR Prospective Trial
2022-01-05101
OA
Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA

Daratumumab联合来那度胺和地塞米松治疗不符合移植条件的新诊断多发性骨髓瘤: MAIA的脆弱亚组分析

LEUKEMIA
IF13.4
2022-01-0259
OAAI
Droplet digital PCR allows vector copy number assessment and monitoring of experimental CAR T cells in murine xenograft models or approved CD19 CAR T cell-treated patients
2021-06-2123
OAAI
Improved survival in multiple myeloma during the 2005-2009 and 2010-2014 periods
LEUKEMIA
IF13.4
2021-06-0713
PREAI
Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab plus bortezomib/thalidomide/dexamethasone in the phase III CASSIOPEIA study
2021-03-0429
OAAI
Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial
LEUKEMIA
IF13.4
2021-01-2216
PREAI